Clinical Trials Logo

Clinical Trial Summary

The primary objective of this study is to determine if exercise, fasting, or eating prior to the molecular breast imaging study will have an effect on the uptake of the tracer in the breast tissue.


Clinical Trial Description

The primary objective of this study is to determine if exercise, fasting, or eating prior to a molecular breast imaging study will have an effect on the uptake of the radiotracer Tc-99m sestamibi in the breast tissue.

Tc-99m sestamibi is primarily extracted by the liver. Changes in hepatic blood flow may therefore influence the amount of radiotracer available for uptake in the breast tissue. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01944215
Study type Interventional
Source Mayo Clinic
Contact
Status Completed
Phase Phase 1
Start date September 2013
Completion date April 2015

See also
  Status Clinical Trial Phase
Recruiting NCT02916329 - In Vivo EGFR-ECD Molecular Imaging Using [68Ga]- Labelling Anti-EGFR Affibody Molecule N/A
Recruiting NCT02916394 - In Vivo IGF-1R Molecular Imaging Using [68Ga]- Labelling Anti-IGF-1R Affibody Molecule N/A
Active, not recruiting NCT03358589 - Molecular Evaluation in Metastatic Breast Cancer N/A
Completed NCT03031522 - EGFR Molecular Classification In Vivo N/A
Recruiting NCT02717221 - In Vivo EGFR Molecular Classification and Treatment Response N/A
Completed NCT03233243 - Rosuvastatin Effect on Atherosclerotic Plaque Metabolism Phase 4
Completed NCT02323217 - I2PETHV - Imidazoline2 Binding Site in Healthy Volunteers Early Phase 1
Enrolling by invitation NCT05575765 - Clinical Validation of Multimodal Digestive Endoscopy